Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December

Ilya Pharma presented at the Redeye unlisted event December 2

FDA open to new endpoints for patients with difficult wounds

FDA opened for 5 new endpoints in Nov 2020 (vs. only 1 until then) following thorough work by FDA’s Inter-center Wound Healing Work group and industry Wound Experts/FDA Clinical Endpoints Project.

Meet Ingemar Kihlstörm - facilitating the next stage of growth

Financing innovations in pharmaceutical development – facilitating the next stage of growth

Operational Report Q3 2020

Meet Margareth Jorvid leading innovations to products

Some thoughts from the CEO

Operational Report Q2 2020

High level operational report summarising key milestones Q2 2020 and forward looking statement.

Ilya Pharma awarded risk-shared funding by EIT Health

Ilya Pharma awarded Euros 5.3 million from EIC Accelerator to fast track Phase II study of first-in-class ILPI100 advanced therapy for wound treatment in people with diabetes

4000 applicants, 72 SMEs awarded, Ilya Pharmas project among the 1.8 % winners!